All In Biotech

Investigational drug · Phase 3

QRX-3

Also called: Eseronate

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure.

Phase 3

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "QRX-3"

First trial start

2025

Oct 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QRX-3", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Kidney Diseases
  • Acute Kidney Injury
  • Kidney Failure
  • Acute Renal Failure (ARF)
  • Acute Tubular Necrosis

Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "QRX-3" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Chronic Kidney Diseases

  • PacibekitugTOUR006, PAC001Phase 33 trials

    Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases

  • rilparencelRenal Autologous Cell Therapy, REACTPhase 32 trials

    Prokidney · Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.